<DOC>
	<DOCNO>NCT02521220</DOCNO>
	<brief_summary>Some study report improved vascular function supplementation L-arginine participant cardiovascular disease ( CVD ) . Several clinical study also begin investigation L-arginine supplementation participant peripheral artery disease ( PAD ) . This particularly important currently limit option available medically manage intermittent leg pain result PAD . Although short-term clinical trial suggest oral L-arginine improve walk distance improve walk speed participant PAD , result consistent . Further , 1 % oral supplement L-arginine available NO production rest metabolise body . A good way provide body substrate produce NO therefore need . The natural amino acid food component , L-citrulline suggest good candidate purpose . L-citrulline , name watermelon citrullus vulgaris first isolate , natural precursor L-arginine . Studies show L-citrulline metabolise body lesser degree compare L-arginine hence effective precursor arginine peripheral tissue , include endothelial cell . Oral L-citrulline supplementation also eliminate unwanted effect associate oral arginine supplementation well tolerate without known side effect . In addition , L-citrulline supplement available over-the-counter . Thus , oral supplementation L-citrulline may new intervention strategy participant PAD . The investigator hypothesize oral food supplement L-citrulline , unlike L-arginine , reverse endothelial dysfunction . In multinational , multicenter , double blind , randomise , placebo-controlled cross-over trial effect L-citrulline peripheral artery disease investigate .</brief_summary>
	<brief_title>L-Citrulline Peripheral Artery Disease</brief_title>
	<detailed_description>The primary aim trial examine whether oral food supplement L-citrulline effect clinical status , walk distance , arterial endothelial function participant PAD . The investigator use double-blinded crossover design patient serve control . Patients enrol two 'treatment ' period twelve week wash-out period 4 week . Patients randomly assign get L-citrulline first placebo second period vice versa . After screen phase 3 week , 'zero-point ' measurement en first 'treatment ' period 12 week start ( placebo food-supplement ) . Then wash-out phase 4 week second 'treatment ' period start ( food-supplement placebo ) In period , 2 week end period , measurement primary secondary outcome do : questionnaire fill , treadmill test flow-mediated dilation ( vessel function ) . The follow-up take another 4 week end phone call check condition patient possible side effect . Since every patient get placebo food-supplement , every patient his/her control .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>40 year old male postmenopausal woman ; male participant must agree use adequate form contraception study period ; 6month history stable intermittent claudication ( IC ) due PAD ; PAD secondary atherosclerosis significant claudication ( Fontaine class II define IC , Fontaine class III define pain rest ) ; IC characterise pain , ache , cramp , numbness severe fatigue involve muscle one low extremity , reproducibly provoke walk relieve rest ; anklebrachial index ( ABI ) rest &lt; 0.9 least 25 % decrease ABI within 1 min exercise recovery ; capacity walk 2 min/15 meter 12 min treadmill use SkinnerGardner protocol ; walk limited claudication , coexist condition ; difference two consecutive baseline exercise treadmill test &lt; 25 % 3weeks runin period ; change medication physical activity within 3 month prior enrolment . Women childbearing potential ; Current enrolment another clinical trial and/or ingestion another investigational product within past 30 day enrolment ; PAD nonatherosclerotic nature ; Fontaine class IV i.e . ulcer gangrene ; leg amputation ankle ; peripheral vascular surgery , sympathectomy , peripheral angioplasty stent insertion within previous 3 month ; myocardial infarction , unstable angina , percutaneous transluminal coronary angioplasty coronary artery bypass graft surgery within previous 3 month ; uncontrolled hypertension ( rest systolic blood pressure ( SBP ) &gt; 190 diastolic blood pressure ( DBP ) &gt; 115 mmHg ) ; hypotension ( SBP &lt; 90mmHg ) ; type I diabetes , proliferative retinopathy ; history disease state surgery affect gastrointestinal absorption ; significant renal disease ( serum creatinine &gt; 3.0 mg/dl ) ; liver disease ( transaminase &gt; 3x upper limit normal , bilirubin &gt; 1.5 time upper limit normal ) ; history treatment malignancy within past 5 year , evidence active malignancy squamous cell basal cell carcinoma skin ; serious infection hypotension associate sepsis last month ; cerebrovascular infarct last 3 month ; autoimmune disorder ( e.g . systemic lupus erythematosis , ulcerative colitis ) ; acute chronic medical condition opinion investigator increase likelihood participant would unable complete study ; unwillingness discontinue arginine Lcitrullinecontaining product , pentoxifylline , Lcarnitine , prostacyclin least 1 month prior study ; condition PAD limit walk distance .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>L-citrulline</keyword>
	<keyword>Endothelial dysfunction</keyword>
</DOC>